Clinical trial
Phase I/II Study of Human Chorionic Gonadotropin and Epidermal Growth Factor Supplementation (Pregnyl®) to Support Tolerance and Repair As Adjunct Therapy in High-Risk or Refractory Acute Graft-Versus-Host Disease
NCT02525029 is registered in ClinicalTrials.gov with Masonic Cancer Center, University of Minnesota as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I/II Study of Human Chorionic Gonadotropin and Epidermal Growth Factor Supplementation (Pregnyl®) to Support Tolerance and Repair As Adjunct Therapy in High-Risk or Refractory Acute Graft-Versus-Host Disease
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- March 31, 2016
- Completion date
- April 30, 2022
- Enrollment
- 53 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.